Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000794599 | SCV000934017 | uncertain significance | Hypertrophic cardiomyopathy | 2018-10-09 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 1239 of the MYBPC3 protein (p.Glu1239Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is present in population databases (rs267602904, ExAC 0.003%). This variant has not been reported in the literature in individuals with MYBPC3-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |